Dynorphin B
Names | |
---|---|
Other names
Dynorphin B-13; Rimorphin
| |
Identifiers | |
3D model (
JSmol ) |
|
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C74H115N21O17 | |
Molar mass | 1570.8354 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Dynorphin B, also known as rimorphin,
Dynorphin B has an identical N-terminal sequence, but different C-terminal sequence to Dynorphin A. In an alanine scan of the non-glycine residues of dynorphin B, it was discovered that Tyr1 and Phe4 residues are critical for both opioid receptor affinity and κ-opioid receptor agonist potency, Arg6 and Arg7 promote κ-opioid affinity and Lys10 contributes to the opioid receptor affinity.[3]
Inducers of Dynorphin B
Cannabinoid CP55,940 and △9-tetrahydrocannabinol (△9-THC) can induce the release of dynorphin B, which in return acts as an agonist of κ-opioid receptors, resulting in the production of antinociception.[4] Similarly, Tyr-D-Arg-Phe-Sar (TAPS) is capable of promoting a release of dynorphin B through the simulation of μ1-opioid receptors, causing a production of antinociception.[5] The antinociceptive effect produced by dynorphin B allows for spinal analgesia.
See also
References
- ^ Dynorphin B - Compound Summary, PubChem.
- ISBN 978-0-8493-8757-9. Retrieved 22 April 2012.
- PMID 28464209.
- S2CID 8616013.
- S2CID 1770295.